A new pooled analysis of the FIBRONEER™-IPF and FIBRONEER™-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases ...

Conflicting findings in environmental epidemiology have long stalled consensus on the health effects of toxic chemicals. A new study suggests that one major reason for these inconsistencies may be the ...

The five medical centers overseen by the University of California have collected more than a decade's worth of surgical data, allowing it to streamline care and improve financial margins, which has ...

Efficacy, safety, and tolerability of tivozanib (TIVO) in heavily pretreated patients (pts) with advanced clear-cell renal cell carcinoma (ccRCC). This is an ASCO Meeting Abstract from the 2024 ASCO ...

Deep, stable and durable reductions in kallikrein observed Among 32 patients who received a 50 mg dose of lonvo-z as of data cutoff: 31 (97%) were attack-free and long-term prophylaxis (LTP)-free 24 ...

April 28, 2025-- Conflicting findings in environmental epidemiology have long stalled consensus on the health effects of toxic chemicals. A new study by Columbia University Mailman School of Public ...